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Targeted intrapulmonary delivery of drugs may reduce systemic toxicity and 
improve treatment efficacy. In the current study, we evaluated effects of the combination 
treatment of aerosolized liposomal amphotericin B (L-AMB) inhalation with 
intraperitoneal micafungin (MCFG) in murine invasive pulmonary aspergillosis. The 
combination of aerosolized L-AMB with intraperitoneal MCFG significantly improved 
survival rate and showed superiority in the fungal burdens and histopathology findings 
compared to control and both monotherapy groups.    
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Invasive pulmonary aspergillosis (IPA) results in significant morbidity and 
mortality in severe immunocompromised patients (6). Targeted intrapulmonary delivery 
of antifungals has potential to reduce systemic toxicity, improve treatment efficacy as 
well as prophylaxis (1, 8), and may be used as an optional route in combination use with 
other systemic antifungals. In the current study, we evaluated the efficacy of aerosolized 
liposomal amphotericin B (L-AMB) either in single and combination with 
intraperitoneally administered micafungin (MCFG) in a murine model of IPA. 
Aspergillus fumigatus MF13 was clinically obtained from a patient admitted to 
the Nagasaki University Hospital. The minimum effective concentration (MEC) of 
MCFG (Astellas Pharmaceuticals Inc., Tokyo, Japan) and the MIC of AMB (SIGMA, St 
Louis, MO, USA) were determined using the microdilution method in accordance to the 
Clinical Laboratory Standards Institute M38-A2 (2). Drug interactions were assessed 
using the checkerboard titration broth microdilution-based method (3) and the fractional 
inhibitory concentration (FIC) index was determined as previously described (5). 
 Six-week old female ICR mice (Charles River Breeding Laboratories, Shiga, 
Japan) were immunosuppressed and then challenged on day zero with 5  106 conidia of 
A. fumigatus MF13 intratracheally for monitoring survival as previously described (7, 
11). Eight-week old female ICR mice were used for fungal burdens and 
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histopathological examination. Mice were immunosuppressed by subcutaneous injection 
of cortisone acetate (Sigma, Tokyo, Japan) at 250 mg/kg and intraperitoneal 
cyclophosphamide (Sigma) at 200 mg/kg on days -2, 0 for survival study. Whereas, only 
cortisone acetate 200 mg/kg was used on days -1, 0 and 1 for fungal burden analysis and 
histopathological examination. Mice were assigned into the following groups, 1) control, 
2) intraperitoneal MCFG, 3) aerosolized L-AMB and 4) combination of intraperitoneal 
MCFG and aerosolized L-AMB treatment. Each group is consisted of 11 and 10 mice 
for survival and fungal burden analysis, respectively. MCFG was administered 
intraperitoneally once daily at 1 mg/kg/day. L-AMB was administered once daily at a 
dose of 8 ml of 1.2 mg/ml per inhalation. Antifungals were initiated 16 hours after 
inoculation and continued for 5 and 3 days for survival and fungal burden analysis, 
respectively. The L-AMB solution was aerosolized using a nebulizer (Muromachi kikai 
Co., Ltd., Tokyo, Japan) and mice were exposed to aerosol treatment for 60 min as 
previously described (9). Control mice were treated with sterile saline. Survival was 
observed until 11 days following the challenge. For fungal burden and hisotpathologcal 
examinations, mice were sacrificed 4 hours after treatment of day 3. CFU per lung 
tissue were calculated and removed lungs were fixed and stained with Grocott’s 
methenamine silver nitrate and hematoxylin-eosin as previously described (11). 
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Survival and fungal burden data are presented in combined of two sets of experiments. 
The blood concentration and the pharmacokinetics of aerosolized L-AMB were 
evaluated. Uninfected mice were also exposed to several concentrations of aerosolized 
L-AMB for 5 days and blood samples and lungs were collected. AMB concentration 
was quantified as previously described (10). Survival curves were generated using the 
Kaplan and Meier method and statistical differences were evaluated by the log rank test. 
To assess fungal burden in lung tissue, geometric means of CFU per organ were 
compared by Student’s t test. Statistical significance was defined as P < 0.05.  
The MIC of AMB against A. fumigatus MF-13 was 1.0 μg/ml and the MEC of 
MCFG was 0.0315 μg/ml. FIC index of AMB and MCFG was 1.5 and drug interaction 
was classified as indifferent (5). 
Survival periods of monotherapy groups, in which mice were treated with 
either intraperitoneal MCFG or aerosolized L-AMB inhalation were significantly longer 
than that of the control group (MCFG alone vs. control, P = 0.006; L-AMB vs. control, 
P < 0.001) (Figure 1). The combination treatment group showed significantly longer 
survival than the intraperitoneal MCFG (P < 0.001), aerosolized L-AMB (P = 0.037) 
and control (P < 0.001) groups. Lung CFU of combination-treated group was 
significantly reduced compared to each of the intraperitoneal MCFG (P < 0.001), 
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aerosolized L-AMB (P = 0.027) and control (P < 0.001) groups (Figure 2). The lungs of 
aerosolized L-AMB- and combination-treated mice showed obviously smaller number 
of hyphae and less foci of inflammation compared to intraperitoneal MCFG and control 
groups (Figure 3). The mean AMB concentrations in the lung tissue following L-AMB 
inhalation at 1.2, 2.6 and 4.0 mg/ml were 35.5, 73.2 and 94.2 μg/g, respectively. 
Recorded levels in the serum were 0.02, 0.06 and 0.06 μg/ml when inhaled L-AMB 
suspensions were administered at 1.2, 2.6 and 4.0 mg/ml, respectively.  
The current study demonstrated the efficacy of monotherapy of aerosolized 
L-AMB in murine IPA model. AMB concentration in lung tissue in our study was 
relatively higher with extremely lower in serum compared to data from another report of 
murine intravenous L-AMB administered model, although experimental conditions 
were not same (10). These results suggested that systemic toxicity generally caused by 
AMB treatment may be reduced by L-AMB inhalation therapy.  
 The effect of combined intraperitoneal MCFG and aerosolized L-AMB 
treatment demonstrated an enhanced survival rate, even though this drug interaction was 
classified as indifferent in vitro. Since 78% of all control mice died in first three days in 
survival analysis, we changed the experimental conditions for analysis of fungal burden 
and histopathological examination. In this model, no mice died before euthanasia, a 
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prerequisite for organ CFU assay. Both fungal burden data and histopathological 
findings supported the survival data in our study. 
 In contrast to our study, Graybill et al. previously reported that combination 
therapy demonstrated a lack of synergistic effects following intravenous L-AMB and 
intraperitoneal MCFG treatment in murine IPA (4). These discrepancies are likely due to 
differences between our model and Graybill’s model including 1) the route of infection, 
2) status of immunosuppression and 3) the administration route of antifungal drugs. 
These differences also suggest that targeted intrapulmonary delivery of drugs by 
inhalation raises the drug concentration at the active site of infection in the lungs, thus 
contributing to the efficacy of combination therapy. Further comparative efficacy 
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Survival curves for mice with IPA (Kaplan-Meier plot). Groups of 11 mice were treated 
with a combination of intraperitoneal MCFG (1 mg/kg/day) and aerosolized L-AMB 
inhalation (8ml of 1.2 mg/ml, open squares), aerosolized L-AMB (8ml of 1.2 mg/ml, 
filled triangles), intraperitoneal MCFG (1 mg/kg/day, open triangles), and control (no 
therapy, filled circles). * P < 0.05 vs. control. ** P < 0.05 vs. control, intraperitoneal 
MCFG group or aerosolized L-AMB group (Log rank test). The survival time for all 
treatment groups was longer than that of controls (P < 0.05). The survival time for the 
combination treatment group was significantly longer than those of the intraperitoneal 
MCFG group and the aerosolized L-AMB group (P < 0.05). 
 
Figure 2 
CFU from homogenized lung tissues of invasive pulmonary aspergilosis mice. Groups 
of 10 mice were treated once per day with a combination of intraperitoneal MCFG (1 
mg/kg/day) and aerosolized L-AMB (8 ml of 1.2 mg/ml), aerosolized L-AMB (8 ml of 
1.2 mg/ml), intraperitoneal MCFG (1 mg/kg/day), and control. CFU counts, as a 
parameter of A. fumigatus burden in the lungs of IPA mice at 4 hours after day 
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3-treatment, are shown. * P < 0.05 (Student’s-t test) 
 
Figure 3 
Histopathology of lung tissues. Both lungs were obtained from IPA mice 4 hours after 
three days treatment with a combination of intraperitoneal MCFG and aerosolized 
L-AMB, aerosolized L-AMB, intraperitoneal MCFG, and saline alone as control. The 
lungs obtained from aerosolized L-AMB- and combination-treated mice showed 
obviously smaller number of hyphae and less foci of inflammation compared to 
intraperitoneal MCFG and control mice. HE; hematoxylin-eosin, GMS; Grocott’s 
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